BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
109.38
+0.45 (0.41%)
At close: Feb 11, 2026, 4:00 PM EST
109.38
0.00 (0.00%)
After-hours: Feb 11, 2026, 5:38 PM EST
BioNTech SE Employees
BioNTech SE had 6,772 employees as of December 31, 2024. The number of employees increased by 639 or 10.42% compared to the previous year.
Employees
6,772
Change (1Y)
639
Growth (1Y)
10.42%
Revenue / Employee
$546,192
Profits / Employee
-$99,034
Market Cap
27.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 11,000 |
| Moderna | 5,800 |
| Incyte | 2,844 |
| Genmab | 2,681 |
| Alnylam Pharmaceuticals | 2,230 |
| argenx SE | 1,599 |
| Insmed | 1,271 |
| Revolution Medicines | 809 |
BNTX News
- 14 days ago - BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer - GlobeNewsWire
- 4 weeks ago - BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund - Business Wire
- 7 weeks ago - BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field - GlobeNewsWire
- 2 months ago - BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
- 2 months ago - BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - GlobeNewsWire
- 2 months ago - BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer - GlobeNewsWire